Search Results - "IFRAH, N"

Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients by Schmidt‐Tanguy, A., Voswinkel, J., Henrion, D., Subra, J. F., Loufrani, L., Rohmer, V., Ifrah, N., Belizna, C.

Get full text

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia by Willems, L, Chapuis, N, Puissant, A, Maciel, T T, Green, A S, Jacque, N, Vignon, C, Park, S, Guichard, S, Herault, O, Fricot, A, Hermine, O, Moura, I C, Auberger, P, Ifrah, N, Dreyfus, F, Bonnet, D, Lacombe, C, Mayeux, P, Bouscary, D, Tamburini, J

“…The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell growth and proliferation, and is constitutively activated in primary acute…”
Get full text

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia by Gökbuget, N, Kelsh, M, Chia, V, Advani, A, Bassan, R, Dombret, H, Doubek, M, Fielding, A K, Giebel, S, Haddad, V, Hoelzer, D, Holland, C, Ifrah, N, Katz, A, Maniar, T, Martinelli, G, Morgades, M, O'Brien, S, Ribera, J-M, Rowe, J M, Stein, A, Topp, M, Wadleigh, M, Kantarjian, H

“…We compared outcomes from a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia…”
Get full text

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial by Willekens, Christophe, Blanchet, Odile, Renneville, Aline, Cornillet-Lefebvre, Pascale, Pautas, Cécile, Guieze, Romain, Ifrah, Norbert, Dombret, Hervé, Jourdan, Eric, Preudhomme, Claude, Boissel, Nicolas

“…In t(8;21)(q22;q22) acute myeloid leukemia, the prognostic value of early minimal residual disease assessed with real-time quantitative polymerase chain…”
Get full text

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML by Park, S, Chapuis, N, Bardet, V, Tamburini, J, Gallay, N, Willems, L, Knight, Z A, Shokat, K M, Azar, N, Viguié, F, Ifrah, N, Dreyfus, F, Mayeux, P, Lacombe, C, Bouscary, D

“…The phosphatidylinositol 3-kinase (PI3K)/Akt and mammalian target of rapamycin complex 1 (mTORC1) signaling pathways are frequently activated in acute…”
Get full text

Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study by de Hollanda, A., Beucher, A., Henrion, D., Ghali, A., Lavigne, C., Lévesque, H., Hamidou, M., Subra, J. F., Ifrah, N., Belizna, C.

“…Objective The presence of systemic and/or immune manifestations in myelodysplasia has been currently reported. The influence of these manifestations on the…”
Get full text

Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia by Tesio, M, Trinquand, A, Ballerini, P, Hypolite, G, Lhermitte, L, Petit, A, Ifrah, N, Baruchel, A, Dombret, H, Macintyre, E, Asnafi, V

“…The tumour suppressor gene PTEN is commonly altered in T-cell acute lymphoblastic leukaemia but its prognostic impact is still debated. We screened a cohort of…”
Get full text

Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire by Mohty, M, Labopin, M, Balère, M L, Socié, G, Milpied, N, Tabrizi, R, Ifrah, N, Hicheri, Y, Dhedin, N, Michallet, M, Buzyn, A, Cahn, J-Y, Bourhis, J-H, Blaise, D, Raffoux, C, Espérou, H, Yakoub-Agha, I

“…This retrospective report assessed the impact of rabbit antithymocyte globulins (ATG), incorporated within a standard myeloablative conditioning regimen prior…”
Get full text

Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients by Nicolas, E, Ramus, C, Berthier, S, Arlotto, M, Bouamrani, A, Lefebvre, C, Morel, F, Garin, J, Ifrah, N, Berger, F, Cahn, J Y, Mossuz, P

“…Cytogenetic stratification remains insufficient for almost half of the acute myeloblastic leukemia (AML) cases, with AML patients requiring subsequent…”
Get full text

TCRα rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome by Villarese, P, Lours, C, Trinquand, A, Le Noir, S, Belhocine, M, Lhermitte, L, Cieslak, A, Tesio, M, Petit, A, LeLorch, M, Spicuglia, S, Ifrah, N, Dombret, H, Langerak, A W, Boissel, N, Macintyre, E, Asnafi, V

“…T-cell acute lymphoblastic leukemia (T-ALL) results from leukemic transformation of T-cell precursors arrested at specific differentiation stages, including an…”
Get full text

A new Leukemia Prognostic Scoring System for refractory relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study by Chevallier, P, Labopin, M, Turlure, P, Prebet, T, Pigneux, A, Hunault, M, Filanovsky, K, Cornillet-Lefebvre, P, Luquet, I, Lode, L, Richebourg, S, Blanchet, O, Gachard, N, Vey, N, Ifrah, N, Milpied, N, Harousseau, J-L, Bene, M-C, Mohty, M, Delaunay, J

“…A simplified prognostic score is presented based on the multivariate analysis of 138 refractory/relapsed acute myeloid leukaemia (AML) patients (median age 55…”
Get full text

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma by LODE, Laurence, EVEILLARD, Marion, GUILHOT, François, CAILLOT, Denis, MARIT, Gérald, MATHIOT, Claire, FACON, Thierry, ATTAL, Michel, HAROUSSEAU, Jean-Luc, MOREAU, Philippe, MINVIELLE, Stéphane, AVET-LOISEAU, Hervé, TRICHET, Valérie, SOUSSI, Thierry, WUILLEME, Soraya, RICHEBOURG, Steven, MAGRANGEAS, Florence, IFRAH, Norbert, CAMPION, Loic, TRAULLE, Catherine

“…Deletion of the 17p13 chromosomal region [del(17p)] is associated with a poor outcome in multiple myeloma. Most of the studies have targeted the TP53 gene for…”
Get full text

Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL by Garand, R, Beldjord, K, Cavé, H, Fossat, C, Arnoux, I, Asnafi, V, Bertrand, Y, Boulland, M-L, Brouzes, C, Clappier, E, Delabesse, E, Fest, T, Garnache-Ottou, F, Huguet, F, Jacob, M-C, Kuhlein, E, Marty-Grès, S, Plesa, A, Robillard, N, Roussel, M, Tkaczuk, J, Dombret, H, Macintyre, E, Ifrah, N, Béné, M C, Baruchel, A

“…Minimal residual disease (MRD) quantification is widely used for therapeutic stratification in pediatric acute lymphoblastic leukemia (ALL). A robust,…”
Get full text

Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC by Tessoulin, B, Ceballos, P, Chevallier, P, Blaise, D, Tournilhac, O, Gauthier, J, Maillard, N, Tabrizi, R, Choquet, S, Carras, S, Ifrah, N, Guillerm, G, Mohty, M, Tilly, H, Socie, G, Cornillon, J, Hermine, O, Daguindau, É, Bachy, E, Girault, S, Marchand, T, Oberic, L, Reman, O, Leux, C, Le Gouill, S

“…Poly-chemotherapy plus rituximab followed by autologous stem cell transplantation (auto-SCT) is standard care for untreated young patients with mantle cell…”
Get full text

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody by CHAPUIS, Nicolas, TAMBURINI, Jérôme, MAYEUX, Patrick, LACOMBE, Catherine, BOUSCARY, Didier, CORNILLET-LEFEBVRE, Pascale, GILLOT, Lucile, BARDET, Valérie, WILLEMS, Lise, PARK, Sophie, GREEN, Alexa S, IFRAH, Norbert, DREYFUS, François

“…Alterations in the PI3K/Akt pathway are found in a wide range of cancers and the development of PI3K inhibitors represents a promising approach to cancer…”
Get full text

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse by Park, S, Chapuis, N, Saint Marcoux, F, Recher, C, Prebet, T, Chevallier, P, Cahn, J-Y, Leguay, T, Bories, P, Witz, F, Lamy, T, Mayeux, P, Lacombe, C, Demur, C, Tamburini, J, Merlat, A, Delepine, R, Vey, N, Dreyfus, F, Béné, M C, Ifrah, N, Bouscary, D

“…The mTORC1 signaling pathway is constitutively activated in almost all acute myelogenous leukemia (AML) patients. We conducted a phase Ib trial combining…”
Get full text

PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study by Familiades, J, Bousquet, M, Lafage-Pochitaloff, M, Béné, M-C, Beldjord, K, De Vos, J, Dastugue, N, Coyaud, E, Struski, S, Quelen, C, Prade-Houdellier, N, Dobbelstein, S, Cayuela, J-M, Soulier, J, Grardel, N, Preudhomme, C, Cavé, H, Blanchet, O, Lhéritier, V, Delannoy, A, Chalandon, Y, Ifrah, N, Pigneux, A, Brousset, P, Macintyre, E A, Huguet, F, Dombret, H, Broccardo, C, Delabesse, É

“…Adult and child B-cell progenitor acute lymphoblastic leukemia (BCP-ALL) differ in terms of incidence and prognosis. These disparities are mainly due to the…”
Get full text

Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party by Horstmann, K, Boumendil, A, Finke, J, Finel, H, Kanfer, E, Milone, G, Russell, N, Bacigalupo, A, Chalandon, Y, Diez-Martin, J L, Ifrah, N, Chacon, M Jurado, Dreger, P

“…The aim of this registry-based retrospective study was to analyze the outcome of second allogeneic hematopoietic SCT (alloHSCT_2) performed in patients with…”
Get full text

Cutaneous and systemic T-cell lymphoma treated with haploidentical bone marrow transplantation by Méchineaud, M, Mercier, M, Le Corre, Y, Croué, A, Ifrah, N, Martin, L

“…Herein, we report a case of systemic cutaneous T-cell lymphoma refractory to standard therapy, the course of which resulted in haplo-identical bone marrow…”
Get full text

P421: LOWER VΓ9VΔ2 T CELLS RELATIVE FREQUENCIES PREDICT POORER SURVIVAL IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA by Le Floch, A.‐C., Orlanducci, F., Le Roy, A., Hamel, J.‐F., Ifrah, N., Cornillet‐Lefebvre, P., Delaunay, J., Récher, C., Delabesse, E., Pigneux, A., Béné, M.‐C., Vey, N., Chretien, A.‐S., Olive, D.

Get full text